Advertisement

The Economics of Rectal Cancer Care: Considerations in Interpretation of the Literature

  • Andrew P. Zbar
  • Nir Horesh
Chapter

Abstract

This chapter provides a general overview of considerations when economic analyses are reported for the management of patients with rectal cancer. Although we have included an assessment of selected European, Australasian and North American variations in reported series as they pertain to rectal cancer for the use of radiotherapy, adjuvant-neoadjuvant chemotherapy and multimodality therapy, we describe more the pitfalls in the interpretation of comparative economic data assessing rectal cancer care.

References

  1. 1.
    Lipscomb J, Yabroff KR, Hornbrook MC, Gigli A, Francisi S, Krahn M, Gatta G, Trama A, Ritwoller DP, Durand-Zaleski I, Salloum R, Chawla N, Angiolini C, Crocetti E, Giusti F, Guzzinati S, Mezzetti M, Miccinesi G, Mariotto A. Comparing cancer care, outcomes, and costs across health systems: charting the course. JNCI Monogr. 2013;46:124–30.CrossRefGoogle Scholar
  2. 2.
    International Agency for Research in Cancer and International Association of Cancer Registries. Cancer incidence in five continents, vol. IX, IARC scientific publication no. 160. Lyon: IARC; 2007.Google Scholar
  3. 3.
    EUROCARE. Survival of cancer patients in Europe. http://www.eurocare.it
  4. 4.
    Organization for Economic Cooperation and Development. Health expenditure. In: OECD factbook 2011–2012: economic, environmental and social statistics. http://www.oecd.org/publications/oecd-factbook-18147364.htm.
  5. 5.
    Gigli A, Warren JL, Yabroff KR, et al. Initial treatment of newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. J Natl Cancer Inst Monogr. 2013;46(1):88–98.CrossRefGoogle Scholar
  6. 6.
    Gatta G, Trama A, Capocaccia R. Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. J Natl Cancer Inst Monogr. 2013;46(1):79–87.CrossRefGoogle Scholar
  7. 7.
    Chawla N, Butler EN, Lund J, Warren JL, Harlan LC, Yabroff KR. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr. 2013;46(1):36–61.CrossRefGoogle Scholar
  8. 8.
    Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, Yabroff KR. Patterns of colorectal cancer care in the United States and Canada: a systematic review. J Natl Cancer Inst Monogr. 2013;46(1):13–35.CrossRefGoogle Scholar
  9. 9.
    Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefGoogle Scholar
  10. 10.
    Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRefGoogle Scholar
  11. 11.
    Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.CrossRefGoogle Scholar
  12. 12.
    Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. Erratum in N Engl J Med. 2009:26;360(9):944. Off PubMed N Engl J Med. 2009:5;360(6):626–33. https://doi.org/10.1056/NEJMhpr0807774.CrossRefGoogle Scholar
  13. 13.
    Medicare Part B drugs and oncology: statement of Mark E. 3. Miller before the Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives; 2006 Jul 13. http://www.medpac.gov/publications/congressional_testimony/071306_Testimony_Part%20B_oncology.pdf. Accessed 16 Jan 2009.
  14. 14.
    Medicare expenditures from the Office of the Actuary. Baltimore: Centers for Medicare & Medicaid Services. http://www.cms.hhs.gov/NationalHealthExpendData/downloads/tables.pdf. Accessed 16 Jan 2009.
  15. 15.
    Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, Ekwueme DU, Yabroff KR, Jemal A. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer. 2017;123(8):1453–63.CrossRefGoogle Scholar
  16. 16.
    Schrag D. The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317–9.CrossRefGoogle Scholar
  17. 17.
    Yabroff KR, Francisi S, Mariotto A, Mezzetti M, Gigli A, Lipscomb J. Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. JNCI Monogr. 2013;46:1–6.CrossRefGoogle Scholar
  18. 18.
    OECD Health Data 2012. Organisation for Economic Co-operation and Development (OECD) Website. http://www.oecd.org/health/health-systems/oecdhealthdata2012.htm. Accessed 3 Jan 2013.
  19. 19.
    Fuchs VR. How and why US health care differs from that in other OECD countries. JAMA. 2013;309(1):33–4.CrossRefGoogle Scholar
  20. 20.
    Denost Q, Saillour F, Masya L, Martinaud HM, Guillon S, Kret M, Rullier E, Quintard B, Solomon M. Benchmarking trial between France and Australia comparing management of primary rectal cancer beyond TME and locally recurrent rectal cancer (PelviCare Trial): rationale and design. BMC Cancer. 2016;16:262.  https://doi.org/10.1186/s12885-016-2286-1.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr. 2013;46(1):62–78.CrossRefGoogle Scholar
  22. 22.
    Elferink MA, van Steenbergen LN, Krijnen P, et al., Working Group Output of the Netherlands Cancer Registry. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer. 2010;46(8):1421–9.CrossRefGoogle Scholar
  23. 23.
    Khani MH, Smedh K. Centralization of rectal cancer surgery improves long-term survival. Color Dis. 2010;12(9):874–9.CrossRefGoogle Scholar
  24. 24.
    Marwan K, Staples MP, Thursfield V, Bell SW. The rate of abdomino-perineal resections for rectal cancer in the state of Victoria, Australia: a population-based study. Dis Colon Rectum. 2010;53(12):1645–51.CrossRefGoogle Scholar
  25. 25.
    Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G. Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics. BMJ. 2010;340:b5479.  https://doi.org/10.1136/bmj.b5479.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Martling A, Granath F, Cedermark B, Johansson R, Holm T. Gender differences in the treatment of rectal cancer: a population based study. Eur J Surg Oncol. 2009;35(4):427–33.CrossRefGoogle Scholar
  27. 27.
    Sigurdsson HK, Søreide JA, Dahl O, Skarstein A, Von Hofacker S, Kørner H. Utilisation of specialist care in patients with incurable rectal cancer. A population-based study from Western Norway. Acta Oncol. 2009;48(3):377–84.CrossRefGoogle Scholar
  28. 28.
    Tilney HS, Heriot AG, Purkayastha S, et al. A national perspective on the decline of abdominoperineal resection for rectal cancer. Ann Surg. 2008;247(1):77–84.CrossRefGoogle Scholar
  29. 29.
    Ptok H, Marusch F, Kuhn R, Gastinger I, Lippert H. Influence of hospital volume on the frequency of abdominoperineal resection and long-term oncological outcomes in low rectal cancer. Eur J Surg Oncol. 2007;33(7):854–61.CrossRefGoogle Scholar
  30. 30.
    Phelip JM, Milan C, Herbert C, et al. Evaluation of the management of rectal cancers before and after the consensus conference in France. Eur J Gastroenterol Hepatol. 2004;16(10):1003–9.CrossRefGoogle Scholar
  31. 31.
    Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Søreide O, Norwegian Rectal Cancer Group. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum. 2004;47(1):48–58.CrossRefGoogle Scholar
  32. 32.
    Engel AF, Oomen JL, Eijsbouts QA, Cuesta MA, van de Velde CJ. Nationwide decline in annual numbers of abdomino-perineal resections: effect of a successful national trial? Color Dis. 2003;5(2):180–4.Google Scholar
  33. 33.
    Farmer KC, Penfold C, Millar JL, et al., Gastrointestinal Committee of the Victorian Cooperative Oncology Group, The Cancer Council of Victoria. Rectal cancer in Victoria in 1994: patterns of reported management. ANZ J Surg. 2002;72(4):265–70.CrossRefGoogle Scholar
  34. 34.
    García-Granero E, Martí-Obiol R, Gómez-Barbadillo J, et al. Impact of surgeon organization and specialization in rectal cancer outcome. Color Dis. 2001;3(3):179–84.CrossRefGoogle Scholar
  35. 35.
    Young JM, Leong DC, Armstrong K, et al. Concordance with national guidelines for colorectal cancer care in New South Wales: a population- based patterns of care study. Med J Aust. 2007;186(6):292–5.PubMedGoogle Scholar
  36. 36.
    Lemmens VE, Verheij CD, Janssen-Heijnen ML, Rutten HJ, Coebergh JW, Gastro-Intestinal Cancer Study Group Comprehensive Cancer Centre South IKZ. Mixed adherence to clinical practice guidelines for colorectal cancer in the Southern Netherlands in 2002. Eur J Surg Oncol. 2006;32(2):168–73.CrossRefGoogle Scholar
  37. 37.
    Hall SE, Holman CD, Platell C, Sheiner H, Threlfall T, Semmens J. Colorectal cancer surgical care and survival: do private health insurance, socioeconomic and locational status make a difference? ANZ J Surg. 2005;75(11):929–35.CrossRefGoogle Scholar
  38. 38.
    Jestin P, Heurgren M, Påhlman L, Glimelius B, Gunnarsson U. Elective surgery for colorectal cancer in a defined Swedish population. Eur J Surg Oncol. 2004;30(1):26–33.CrossRefGoogle Scholar
  39. 39.
    Chiappa A, Zbar AP, Bertani E, Biella F, Audisio RA, Staudacher C. Surgical outcomes for colorectal cancer patients including the elderly. Hepato-Gastroenterology. 2001;48(38):440–4.PubMedGoogle Scholar
  40. 40.
    Pisu M, Richardson LC, Kim YI, et al. Less-than-standard treatment in rectal cancer patients: which patients are at risk [published online ahead of print April 2, 2010]? J Natl Med Assoc. 2010;102(3):190–8.CrossRefGoogle Scholar
  41. 41.
    Latosinsky S, Turner D. Local recurrence after rectal cancer treatment in Manitoba [published online ahead of print February 2, 2009]. Can J Surg. 2009;52(1):45–50.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we under- treating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007;246(2):215–21.CrossRefGoogle Scholar
  43. 43.
    Ricciardi R, Virnig BA, Madoff RD, Rothenberger DA, Baxter NN. The status of radical proctectomy and sphincter-sparing surgery in the United States. Dis Colon Rectum. 2007;50(8):1119–27, discussion 1126–1127.CrossRefGoogle Scholar
  44. 44.
    Phang PT, MacFarlane JK, Taylor RH, et al. Practice patterns and appropriateness of rectal cancer management in British Columbia. BC Med J. 2003;45(7):324–9.Google Scholar
  45. 45.
    Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study [published online ahead of print October 31, 2001]. Ann Surg. 2001;234(5):641–51.CrossRefGoogle Scholar
  46. 46.
    Marusch F, Koch A, Schmidt U, Pross M, Gastinger I, Lippert H. Hospital caseload and the results achieved in patients with rectal cancer. Br J Surg. 2001;88(10):1397–402.CrossRefGoogle Scholar
  47. 47.
    Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92(5):615–23.CrossRefGoogle Scholar
  48. 48.
    Gatta G, Zigon G, Aareleid T, et al. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCARE high resolution study. Acta Oncol. 2010;49(6):776–83.CrossRefGoogle Scholar
  49. 49.
    Vulto JC, Lybeert ML, Louwman MW, Poortmans PM, Coebergh JW. Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):464–71.CrossRefGoogle Scholar
  50. 50.
    Hansen MH, Kjaeve J, Revhaug A, Eriksen MT, Wibe A, Vonen B, Norwegian Rectal Cancer Group. Impact of radiotherapy on local recurrence of rectal cancer in Norway. Br J Surg. 2007;94(1):113–8.CrossRefGoogle Scholar
  51. 51.
    Ng VV, Tytherleigh MG, Fowler L, Farouk R. Subspecialisation and its effect on the management of rectal cancer. Ann R Coll Surg Engl. 2006;88(2):181–4.CrossRefGoogle Scholar
  52. 52.
    Birbeck KF, Macklin CP, Tiffin NJ, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235(4):449–57.CrossRefGoogle Scholar
  53. 53.
    Faivre-Finn C, Benhamiche AM, Maingon P, Janoray P, Faivre J. Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. Radiother Oncol. 2000;57(2):137–42.CrossRefGoogle Scholar
  54. 54.
    Carsin AE, Sharp L, Cronin-Fenton DP, Céilleachair AO, Comber H. Inequity in colorectal cancer treatment and outcomes: a population-based study [published online ahead of print July 1, 2008]. Br J Cancer. 2008;99(2):266–74.CrossRefGoogle Scholar
  55. 55.
    Coriat R, Mahboubi A, Lejeune C, Bouvier AM, Bedenne L, Bonithon-Kopp C. How do gastroenterologists follow patients with colorectal cancer after curative surgical resection? A three-year population-based study. Gastroenterol Clin Biol. 2007;31(11):950–5.CrossRefGoogle Scholar
  56. 56.
    McGrath DR, Leong DC, Armstrong BK, Spigelman AD. Management of colorectal cancer patients in Australia: the National Colorectal Cancer Care Survey. ANZ J Surg. 2004;74(1–2):55–64.CrossRefGoogle Scholar
  57. 57.
    Kuo I, Wong JH, Roy-Chowdhury S, Lum SS, Morgan JW, Kazanjian K. The use of pelvic radiation in stage II rectal cancer: a population-based analysis [published online ahead of print October 26, 2010]. Am Surg. 2010;76(10):1092–5.PubMedGoogle Scholar
  58. 58.
    Lin C, Charlton ME, Meza JL, Enke CA, Loberiza FR Jr. Temporal and regional variations in the use of preoperative radiation therapy for rectal cancer. Am J Clin Oncol. 2010;33(5):443–7.CrossRefGoogle Scholar
  59. 59.
    Demers AA, Latosinsky S, Turner D. Survival and treatment trends of rectal cancer patients in a population with suboptimal local control. Eur J Surg Oncol. 2008;34(6):655–61.CrossRefGoogle Scholar
  60. 60.
    Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008;112(4):789–99.CrossRefGoogle Scholar
  61. 61.
    Baxter NN, Rothenberger DA, Morris AM, Bullard KM. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. Dis Colon Rectum. 2005;48(1):9–15.CrossRefGoogle Scholar
  62. 62.
    Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from a randomized multicenter trial. Ann Surg. 1990;211:187–95.CrossRefGoogle Scholar
  63. 63.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefGoogle Scholar
  64. 64.
    Martijn H, Vulto JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer. 2007;43:2301–6.CrossRefGoogle Scholar
  65. 65.
    Rutten H, Dulk M, Lemmens V, et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. Eur J Cancer. 2007;43:2295–300.CrossRefGoogle Scholar
  66. 66.
    Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9:494–501.Google Scholar
  67. 67.
    Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer. 2007;96(4):546–50.CrossRefGoogle Scholar
  68. 68.
    Robinson B, Frizelle F, Dickson M, Frampton C. Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts. N Z Med J. 2005;118(1210):U1323.PubMedGoogle Scholar
  69. 69.
    Romanus D, Weiser MR, Skibber JM, et al. Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: an NCCN institutional analysis [published online ahead of print September 17, 2009]. J Natl Compr Cancer Netw. 2009;7(8):895–904.CrossRefGoogle Scholar
  70. 70.
    Pitchforth E, Russell E, Van der Pol M. Access to specialist cancer care: is it equitable? Br J Cancer. 2002;87(11):1221–6.CrossRefGoogle Scholar
  71. 71.
    Drug Utilization Review Team in Oncology. Adjuvant systemic therapies in patients with colorectal cancer: an audit on clinical practice in Italy. Tumori. 2005;91(6):472–6.Google Scholar
  72. 72.
    Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005;16(5):767–72.CrossRefGoogle Scholar
  73. 73.
    Alter E, Phelip JM, Guilhot JN, Matysiak M, Vermorel M, Roblin X. Adjuvant chemotherapy for stage II colon cancer: influence of care structures’ characteristics on a controversial clinical practice. Eur J Gastroenterol Hepatol. 2007;19(11):995–1001.CrossRefGoogle Scholar
  74. 74.
    Kube R, Ptok H, Wolff S, Lippert H, Gastinger I, Study Group Colon/Rectum Carcinoma (Primary Tumour). Quality of medical care in colorectal cancer in Germany. Onkologie. 2009;32(1–2):25–9.PubMedGoogle Scholar
  75. 75.
    Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101(10):2308–18.CrossRefGoogle Scholar
  76. 76.
    Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97(16):1211–20.CrossRefGoogle Scholar
  77. 77.
    Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD. Residual treatment disparities after oncology referral for rectal cancer. J Natl Cancer Inst. 2008;100(10):738–44.CrossRefGoogle Scholar
  78. 78.
    Francisi S, Guzzinati S, Mezzetti M, Crocetti E, Giusti F, Miccinesi G, Paci E, Angiolini C, Gigli A. Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC. 2013;13:329.Google Scholar
  79. 79.
    Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease-specific costs of case application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249–59.CrossRefGoogle Scholar
  80. 80.
    Klemp M, Fronsdal KB, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess. 2011;27:77–83.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrew P. Zbar
    • 1
    • 2
  • Nir Horesh
    • 3
  1. 1.Department of Surgery and Transplantation, Department of Surgery BChaim Sheba Medical Center, Tel Hashomer HospitalRamat GanIsrael
  2. 2.Department of Anatomy and NeuroscienceThe University of MelbourneParkvilleAustralia
  3. 3.Department of Surgery and TransplantationChaim Sheba Medical CenterRamat GanIsrael

Personalised recommendations